19 related articles for article (PubMed ID: 22108242)
1. Modelling the regulation of telomere length: the effects of telomerase and G-quadruplex stabilising drugs.
Hirt BV; Wattis JA; Preston SP
J Math Biol; 2014 May; 68(6):1521-52. PubMed ID: 23620229
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
[TBL] [Abstract][Full Text] [Related]
3. Biological activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is associated with telomere capping alteration.
Leonetti C; Amodei S; D'Angelo C; Rizzo A; Benassi B; Antonelli A; Elli R; Stevens MF; D'Incalci M; Zupi G; Biroccio A
Mol Pharmacol; 2004 Nov; 66(5):1138-46. PubMed ID: 15304549
[TBL] [Abstract][Full Text] [Related]
4. Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism.
Phatak P; Cookson JC; Dai F; Smith V; Gartenhaus RB; Stevens MF; Burger AM
Br J Cancer; 2007 Apr; 96(8):1223-33. PubMed ID: 17406367
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities.
Rizzo A; Iachettini S; Zizza P; Cingolani C; Porru M; Artuso S; Stevens M; Hummersone M; Biroccio A; Salvati E; Leonetti C
J Exp Clin Cancer Res; 2014 Oct; 33(1):81. PubMed ID: 25288403
[TBL] [Abstract][Full Text] [Related]
6. Trisubstituted acridines as G-quadruplex telomere targeting agents. Effects of extensions of the 3,6- and 9-side chains on quadruplex binding, telomerase activity, and cell proliferation.
Moore MJ; Schultes CM; Cuesta J; Cuenca F; Gunaratnam M; Tanious FA; Wilson WD; Neidle S
J Med Chem; 2006 Jan; 49(2):582-99. PubMed ID: 16420044
[TBL] [Abstract][Full Text] [Related]
7. The effects of a telomere destabilizing agent on cancer cell-cycle dynamics--integrated modelling and experiments.
Hirt BV; Wattis JA; Preston SP; Laughton CA
J Theor Biol; 2012 Feb; 295():9-22. PubMed ID: 22108242
[TBL] [Abstract][Full Text] [Related]
8. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Raymond E; Faivre S; Dieras V; Von Hoff D
Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
